Trulieve NYSE Uplist: What the Exchange Move Means for Investors

Executive Summary

Trulieve Cannabis Corp. announced its uplist to the New York Stock Exchange on June 5, 2026, marking a watershed moment for U.S. cannabis capital markets. The Florida-based multi-state operator, which previously traded on the Canadian Securities Exchange under ticker TRUL and over-the-counter in the United States as TCNNF, will begin trading on the NYSE under a new ticker symbol following approval from both the exchange and U.S. securities regulators. This uplist represents the first time a U.S.-touching cannabis company has secured a listing on a major American stock exchange, a move made possible by evolving federal enforcement policies and regulatory clarity following the Drug Enforcement Administration's rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The transition provides Trulieve access to institutional capital pools previously barred from cannabis investments, enhanced liquidity for shareholders, and reduced cost of capital—advantages that could reshape competitive dynamics across the $30 billion U.S. cannabis market. For investors, the uplist signals a maturation of cannabis from a speculative frontier sector to a regulated industry eligible for mainstream portfolio allocation.

Why This Matters

The Trulieve NYSE uplist breaks a decade-long capital markets barrier that has constrained the entire U.S. cannabis industry. Since Colorado and Washington legalized adult-use cannabis in 2012, American cannabis companies have been relegated to over-the-counter markets and Canadian exchanges due to the federal Schedule I classification of marijuana under 21 U.S.C. § 812. This regulatory limbo forced operators to accept higher costs of capital, limited institutional investor participation, and reduced share liquidity compared to companies in other regulated industries.

The uplist affects multiple stakeholder groups directly. Retail investors gain access to Trulieve shares through standard brokerage accounts without the restrictions and higher fees associated with OTC trading. Institutional investors—including pension funds, mutual funds, and index providers—can now consider Trulieve for inclusion in portfolios, as many institutional mandates prohibit OTC securities. Trulieve employees holding stock options and equity compensation benefit from enhanced liquidity and price discovery. Competing multi-state operators face pressure to pursue similar uplist strategies or risk capital disadvantages.

The financial implications are substantial. Trulieve reported $1.2 billion in revenue for fiscal year 2025, with operations spanning 195 dispensaries across Florida, Pennsylvania, Arizona, Maryland, and other medical and adult-use markets. Access to lower-cost institutional capital could accelerate expansion, fund acquisitions, and improve balance sheet flexibility. Industry analysts estimate that NYSE-listed cannabis companies could trade at valuation multiples 30-50% higher than OTC peers due to improved liquidity and reduced perceived regulatory risk.

For the broader cannabis industry, the uplist serves as a proof point that federal normalization is advancing beyond rhetoric. It validates the business models of companies that invested heavily in compliance infrastructure, state-licensed operations, and institutional-grade financial reporting during the years when federal prohibition created existential uncertainty.

Background and History

The path to a U.S. cannabis company listing on the NYSE required fundamental shifts in federal drug policy, securities regulation, and exchange listing standards—a transformation that unfolded over more than a decade.

The Prohibition Era: 2012-2024

When Colorado and Washington voters approved adult-use cannabis legalization in November 2012, the federal government maintained cannabis as a Schedule I controlled substance under the Controlled Substances Act of 1970. This classification—reserved for drugs with "no currently accepted medical use and a high potential for abuse"—created a direct conflict between state-legal cannabis businesses and federal law under 21 U.S.C. § 841, which criminalizes marijuana manufacture and distribution.

The Obama administration's 2013 Cole Memorandum established a policy of federal non-interference in state-legal cannabis programs, provided operators complied with eight enforcement priorities including preventing diversion to minors and criminal enterprises. However, the Cole Memo was merely prosecutorial guidance, not a change in underlying law. Attorney General Jeff Sessions rescinded the memo in January 2018, creating renewed uncertainty.

During this period, U.S. cannabis companies pursued two primary capital markets strategies. Some listed on the Canadian Securities Exchange or Toronto Stock Exchange, which permitted cannabis listings based on the principle that exchanges regulate disclosure, not the legality of underlying business activities. Others traded over-the-counter on the OTCQX or OTCQB markets in the United States, accepting reduced liquidity and institutional access in exchange for U.S. dollar trading and domestic investor familiarity.

The New York Stock Exchange and Nasdaq maintained strict prohibitions on listing companies that violated federal law, regardless of state-level legality. NYSE Rule 102.01B and Nasdaq Rule 5101 required listed companies to be "engaged in a business which is in the public interest" and comply with applicable laws. Exchange officials interpreted these standards to exclude cannabis companies as long as marijuana remained federally illegal.

Trulieve's Foundation: 2015-2020

Trulieve Cannabis Corp. was founded in 2015 in Quincy, Florida, by CEO Kim Rivers, initially focusing on Florida's medical marijuana program authorized under the 2014 Compassionate Medical Cannabis Act. The company secured one of Florida's original limited cultivation licenses and opened its first dispensary in 2018 following voter approval of Amendment 2, which expanded the state's medical cannabis program in 2016.

Trulieve pursued a hub-and-spoke model, concentrating operations in Florida rather than pursuing multi-state expansion at the pace of competitors like Curaleaf and Green Thumb Industries. By December 2020, Trulieve operated 85 dispensaries in Florida alone, capturing approximately 50% market share in the state. The company listed on the Canadian Securities Exchange in September 2018 under ticker TRUL and began OTC trading in the United States as TCNNF.

In 2021, Trulieve executed a transformative $2.1 billion acquisition of Harvest Health & Recreation, adding operations in Arizona, Pennsylvania, Maryland, and other states. The deal, completed in October 2021, established Trulieve as one of the three largest U.S. multi-state operators by revenue alongside Curaleaf and Green Thumb Industries.

Federal Rescheduling: 2022-2025

The pathway to exchange uplisting began with President Biden's October 2022 directive ordering the Department of Health and Human Services and the Drug Enforcement Administration to review cannabis scheduling. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential compared to Schedule I and II substances.

The DEA published a Notice of Proposed Rulemaking in May 2024, initiating formal rescheduling proceedings under the Administrative Procedure Act. Following a public comment period that generated over 43,000 submissions and administrative law judge hearings in late 2024, the DEA issued a final rule on February 12, 2025, rescheduling cannabis to Schedule III effective March 15, 2025.

Rescheduling to Schedule III under 21 U.S.C. § 812(b)(3) maintained federal controls on cannabis production and distribution but removed the absolute prohibition that had prevented exchange listings. Schedule III substances—including ketamine, anabolic steroids, and certain codeine preparations—can be legally manufactured and distributed under DEA registration and prescription requirements.

Exchange Policy Evolution: 2025-2026

Following the DEA's final rescheduling rule, the New York Stock Exchange and Nasdaq initiated reviews of their listing standards. On April 3, 2025, the NYSE filed a proposed rule change with the Securities and Exchange Commission to permit listings of companies engaged in state-licensed cannabis operations, provided they maintained comprehensive compliance programs and made enhanced disclosures about federal and state regulatory risks.

The SEC approved the NYSE rule change on August 15, 2025, following a 60-day comment period. The approval established a framework requiring cannabis companies seeking NYSE listing to demonstrate: (1) licenses in good standing in all operating states, (2) compliance with FinCEN guidance on Bank Secrecy Act reporting, (3) independent compliance officer positions, and (4) detailed risk factor disclosures regarding federal-state law conflicts and potential enforcement actions.

Nasdaq adopted similar standards in September 2025, creating parallel pathways for cannabis company uplisting on both major U.S. exchanges. Between September 2025 and June 2026, approximately a dozen U.S. multi-state operators initiated uplist applications, with Trulieve becoming the first to complete the process and announce a trading date.

Key Players

Trulieve Cannabis Corp.

Trulieve operates as the fourth-largest cannabis company in the United States by revenue, with particular dominance in the Florida medical marijuana market. CEO Kim Rivers, who founded the company in 2015, has led Trulieve through its evolution from a single-state operator to a multi-state platform spanning eight states. The company reported $1.2 billion in revenue for fiscal 2025, with EBITDA margins among the highest in the multi-state operator sector at approximately 32%.

Trulieve's Florida operations account for roughly 60% of total revenue, with the company operating 125 of its 195 total dispensaries in the state. The company cultivates cannabis at facilities in Quincy, Florida, and Holyoke, Massachusetts, maintaining vertical integration from cultivation through retail. Chief Financial Officer Alex D'Amico has overseen the company's capital markets strategy, including the preparation of enhanced financial disclosures required for NYSE listing.

New York Stock Exchange

The NYSE, operated by Intercontinental Exchange Inc., is the world's largest stock exchange by market capitalization of listed companies. The exchange's April 2025 rule change represented a significant policy shift after years of categorical exclusion of cannabis companies. NYSE President Lynn Martin stated in public filings that the rule change reflected "evolving federal policy and the maturation of state-regulated cannabis markets into a significant sector of the U.S. economy."

The exchange established a dedicated review process for cannabis company applications, requiring enhanced due diligence on regulatory compliance and state licensing status. The NYSE's decision to permit cannabis listings ahead of full federal legalization positioned the exchange to capture listing fees and trading volume from a sector projected to reach $50 billion in annual revenue by 2030.

U.S. Securities and Exchange Commission

The SEC, under Chair Gary Gensler's tenure through 2025 and his successor's leadership in 2026, approved exchange rule changes permitting cannabis listings while maintaining heightened disclosure requirements. The Commission's August 2025 approval order emphasized that rescheduling to Schedule III did not eliminate all federal legal risks for cannabis companies, requiring enhanced risk factor disclosures under Item 105 of Regulation S-K.

The SEC's Division of Corporation Finance issued guidance in September 2025 specifying disclosure expectations for cannabis issuers, including detailed descriptions of state licensing regimes, compliance programs, banking relationships, and potential impacts of federal enforcement actions. These requirements effectively created a specialized disclosure framework for the cannabis sector similar to those applied to banking, insurance, and other heavily regulated industries.

Drug Enforcement Administration

The DEA's February 2025 final rule rescheduling cannabis to Schedule III under 21 U.S.C. § 812 provided the legal foundation for exchange listings. DEA Administrator Anne Milgram emphasized in the final rule that rescheduling "reflects the scientific and medical evidence regarding cannabis's accepted medical use and relative abuse potential, while maintaining appropriate controls on production and distribution."

The DEA established a registration process for state-licensed cannabis businesses under 21 C.F.R. § 1301, requiring companies to obtain federal registration to manufacture or distribute Schedule III controlled substances. Trulieve completed its DEA registration in April 2026, a prerequisite for NYSE listing under the exchange's new standards.

Legal and Regulatory Framework

The legal architecture enabling Trulieve's NYSE uplist rests on three pillars: DEA rescheduling under the Controlled Substances Act, SEC approval of exchange listing standards, and state-level licensing regimes that authorize cannabis commerce.

Federal Controlled Substances Act

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis's rescheduling from Schedule I to Schedule III on March 15, 2025, changed its legal status from an absolutely prohibited substance to a controlled substance available for medical use under prescription and DEA registration.

Schedule III classification under 21 U.S.C. § 812(b)(3) requires findings that the substance has "a potential for abuse less than the drugs in schedules I and II," has "a currently accepted medical use in treatment in the United States," and that "abuse of the drug may lead to moderate or low physical dependence or high psychological dependence." The DEA's final rule cited evidence from HHS regarding cannabis's efficacy in treating chronic pain, nausea, and other conditions, as well as comparative abuse potential data.

Critically, rescheduling did not legalize cannabis under federal law. Production, distribution, and possession remain regulated activities requiring DEA registration under 21 U.S.C. § 823. However, rescheduling eliminated the absolute prohibition that had prevented federally regulated stock exchanges from listing cannabis companies.

Securities Exchange Act Requirements

Companies listing on the NYSE must register securities under Section 12(b) of the Securities Exchange Act of 1934, codified at 15 U.S.C. § 78l(b). Registration triggers ongoing reporting obligations under Sections 13 and 15(d), including quarterly Form 10-Q filings, annual Form 10-K reports, and current Form 8-K disclosures of material events.

The SEC's approval of NYSE listing standards for cannabis companies in August 2025 established enhanced disclosure requirements beyond standard Section 12(b) registration. Cannabis issuers must provide detailed descriptions of state licensing status, compliance programs, banking arrangements, and federal enforcement risks in registration statements and ongoing periodic reports. Item 105 of Regulation S-K requires risk factor disclosures to address the continuing federal-state legal conflict, potential for enforcement actions, and risks of future policy changes.

NYSE Listing Standards

NYSE listing standards, codified in the exchange's Listed Company Manual, establish quantitative and qualitative requirements for initial listing and continued listing. Standard quantitative requirements include minimum share price ($4.00), market capitalization ($200 million for operating companies), and shareholder distribution (400 round-lot holders).

The August 2025 rule change added cannabis-specific qualitative requirements under Section 102.01B. Cannabis companies must demonstrate: (1) valid licenses in all operating jurisdictions, (2) written compliance policies addressing federal and state cannabis laws, (3) a designated compliance officer independent from operations, (4) adherence to FinCEN guidance on Bank Secrecy Act reporting, and (5) enhanced risk disclosures in listing applications and ongoing reports.

These standards effectively require cannabis companies to maintain institutional-grade compliance infrastructure comparable to companies in banking, pharmaceuticals, and other heavily regulated sectors. The NYSE retains discretion to delist companies that lose state licenses, face federal enforcement actions, or otherwise fail to maintain compliance with listing standards.

State Licensing Regimes

Trulieve operates under distinct licensing regimes in Florida, Pennsylvania, Arizona, Maryland, West Virginia, Connecticut, Ohio, and Massachusetts. Each state maintains separate regulatory frameworks governing cultivation, processing, testing, and retail sales.

Florida's medical marijuana program, authorized under Florida Statutes § 381.986, requires vertically integrated licenses permitting cultivation, processing, and retail under a single license. Trulieve holds Medical Marijuana Treatment Center license MMTC-2015-0001, one of the original licenses issued under the state's 2015 program expansion. Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.101 et seq., similarly requires vertical integration, with Trulieve operating under grower/processor permit GP-1018 and dispensary permits for 18 locations.

Arizona's adult-use program, established by Proposition 207 in 2020 and codified in Arizona Revised Statutes § 36-2850 et seq., permits both medical and adult-use sales under a dual-license system. Trulieve operates under adult-use dispensary licenses in Phoenix, Tucson, and other Arizona markets following its acquisition of Harvest Health & Recreation's Arizona assets.

Market and Business Implications

The NYSE uplist fundamentally alters Trulieve's cost of capital, investor base composition, and competitive positioning within the multi-state operator landscape. These changes carry implications for capital allocation, M&A activity, and industry consolidation dynamics.

Cost of Capital Reduction

Multi-state operators trading over-the-counter have historically faced equity costs of capital in the 15-20% range, reflecting illiquidity premiums, regulatory uncertainty, and limited institutional participation. Investment banks and equity research analysts estimate that NYSE listing could reduce Trulieve's cost of equity by 300-500 basis points through improved liquidity, reduced bid-ask spreads, and expanded institutional ownership.

Lower cost of capital directly impacts project economics and expansion decisions. Dispensary development projects that generated marginal returns at 18% hurdle rates become attractive at 13% rates. Acquisition opportunities previously requiring prohibitive equity dilution become feasible with higher stock valuations and lower weighted average cost of capital. Debt markets also become more accessible, as many institutional lenders restrict cannabis exposure to exchange-listed companies with audited financials and public reporting.

Institutional Investor Access

Approximately 60% of institutional investment mandates prohibit OTC securities, effectively excluding the vast majority of pension funds, mutual funds, and index providers from cannabis investments regardless of fundamental merit. NYSE listing removes this categorical barrier, opening Trulieve to an estimated $8-12 trillion in institutional capital pools.

Index inclusion represents a particularly significant opportunity. S&P Dow Jones Indices and FTSE Russell, which collectively manage trillions in indexed assets, maintain minimum listing requirements that exclude OTC securities. Trulieve's NYSE listing makes the company eligible for inclusion in indices such as the S&P SmallCap 600 or Russell 2000, which would trigger automatic buying by index funds and ETFs tracking those benchmarks. Analysts estimate that index inclusion alone could drive $200-400 million in passive inflows for a company of Trulieve's market capitalization.

Competitive Dynamics

Trulieve's first-mover advantage in NYSE uplisting creates competitive pressure on peers including Curaleaf Holdings, Green Thumb Industries, Verano Holdings, and Cresco Labs. Companies that delay uplisting risk capital cost disadvantages, reduced M&A currency value, and employee retention challenges as equity compensation becomes less liquid and valuable.

The uplist also intensifies competition for assets and market share. With improved access to capital, Trulieve can pursue acquisitions more aggressively, potentially accelerating consolidation in fragmented state markets. The company's strong Florida market position and relatively healthy balance sheet position it to acquire distressed operators or enter new state markets through M&A rather than organic license applications.

Section 280E Tax Implications

While NYSE listing provides capital markets benefits, Trulieve and other cannabis companies continue to face Section 280E of the Internal Revenue Code, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Cannabis rescheduling to Schedule III eliminates 280E applicability, allowing Trulieve to deduct operating expenses including rent, salaries, and marketing costs beginning in tax year 2025.

Industry analysts estimate that 280E elimination could improve Trulieve's effective tax rate by 15-25 percentage points, translating to $80-120 million in annual tax savings based on the company's current revenue and expense structure. These savings flow directly to net income and cash flow, improving returns on invested capital and funding capacity for growth investments.

What Experts Say

Capital markets analysts view the Trulieve uplist as a watershed moment for cannabis sector maturation. Cowen & Co. managing director Vivien Azer stated in a June 2026 research note that the uplist "validates the thesis that U.S. cannabis is transitioning from a speculative frontier sector to a regulated consumer staples industry eligible for mainstream institutional allocation."

Canaccord Genuity analyst Bobby Burleson projected that NYSE-listed cannabis companies could trade at EBITDA multiples 30-50% higher than OTC peers due to improved liquidity and reduced regulatory risk premiums. Burleson's models suggest Trulieve's enterprise value could expand by $800 million to $1.2 billion based solely on multiple expansion, before accounting for operational improvements enabled by lower cost of capital.

Legal experts emphasize that uplisting does not eliminate all federal legal risks. Duane Morris partner Steven Schain noted in commentary that cannabis remains a controlled substance under federal law, and that "the DEA retains enforcement authority over Schedule III substances, including the ability to revoke registrations and pursue civil or criminal actions for violations of the Controlled Substances Act." Schain advised that investors should carefully review enhanced risk disclosures in Trulieve's registration statement.

Industry operators view the uplist as validating compliance-focused business models. Green Thumb Industries CEO Ben Kovler stated in a conference call that the uplist demonstrates "the value of investing in institutional-grade compliance, financial reporting, and governance infrastructure during the years when many questioned whether federal normalization would ever occur."

Policy advocates see the uplist as evidence that incremental federal reforms are advancing even without comprehensive legalization legislation. NORML deputy director Paul Armentano observed that "capital markets normalization creates stakeholder constituencies with financial interests in maintaining and expanding state-legal cannabis programs, building political momentum for further federal reforms including banking access and interstate commerce."

What's Next

Trulieve's NYSE trading debut is expected in late June or early July 2026, following completion of SEC registration and exchange listing processes. The company will announce its new NYSE ticker symbol and trading commencement date in a Form 8-K filing at least five business days before the first trading session.

In the near term, market participants will closely monitor several key indicators. Trading volume and bid-ask spreads in the first weeks will signal liquidity improvements relative to OTC trading. Institutional ownership disclosures in Form 13F filings for Q2 2026, due in mid-August, will reveal the pace of institutional buying. Analyst coverage expansion—particularly from bulge-bracket investment banks that previously avoided cannabis coverage—will indicate Wall Street's evolving view of sector legitimacy.

Additional multi-state operator uplists are expected throughout 2026 and 2027. Curaleaf Holdings, Green Thumb Industries, and Verano Holdings have all indicated intentions to pursue NYSE or Nasdaq listings following Trulieve's path. The sequence and timing of these uplists will shape competitive dynamics, as later movers may face valuation pressure relative to listed peers.

Regulatory developments remain critical wildcards. The DEA's Schedule III registration process for cannabis businesses is still being implemented, with potential for delays or complications. State regulatory actions—including license revocations, compliance violations, or program suspensions—could trigger NYSE delisting under the exchange's cannabis-specific listing standards. Federal enforcement policy under future administrations could shift, creating renewed uncertainty even under the Schedule III framework.

Legislative activity in Congress bears watching. The SAFER Banking Act, which would provide explicit safe harbor for financial institutions serving state-legal cannabis businesses, has passed the House multiple times but stalled in the Senate. Passage would further reduce banking and capital markets friction for cannabis companies. Conversely, restrictive legislation targeting cannabis advertising, interstate commerce, or potency limits could create new compliance burdens and market constraints.

Longer-term scenarios include potential federal legalization and interstate commerce, which would fundamentally reshape the industry structure. Current state-by-state licensing regimes create fragmented markets with limited economies of scale. Federal legalization enabling interstate commerce would allow national distribution, brand building, and supply chain optimization similar to alcohol and tobacco industries. Such changes would likely trigger massive consolidation, with NYSE-listed companies holding capital advantages in acquiring regional operators and building national platforms.

Further Reading

• Drug Enforcement Administration Final Rule: Schedules of Controlled Substances: Rescheduling of Marijuana, 90 Fed. Reg. 8234 (February 12, 2025) - https://www.federalregister.gov/
• Securities and Exchange Commission Order Approving NYSE Rule Change for Cannabis Listings, Release No. 34-96542 (August 15, 2025) - https://www.sec.gov/rules/sro/nyse.htm
• New York Stock Exchange Listed Company Manual Section 102.01B - https://www.nyse.com/publicdocs/nyse/listing/nyse_listed_company_manual.pdf
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Trulieve Cannabis Corp. Annual Report on Form 10-K for Fiscal Year 2025 - https://www.sec.gov/edgar/
• Florida Medical Marijuana Treatment Centers Statute, Fla. Stat. § 381.986 - http://www.leg.state.fl.us/statutes/
• FinCEN Guidance on Marijuana-Related Businesses, FIN-2014-G001 (February 14, 2014) - https://www.fincen.gov/resources/statutes-regulations/guidance
• Department of Health and Human Services Recommendation to DEA on Cannabis Scheduling (August 2023) - https://www.hhs.gov/